129 related articles for article (PubMed ID: 38679983)
1. Prevalence of High-Risk HPV Detection and HPV Vaccination in Cervical Cancer Screening During the HPV Vaccination Era at Siriraj Hospital - Thailand's Largest National Tertiary Referral Center.
Chaopotong P; Laiwejpithya S; Areeswate C
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1241-1245. PubMed ID: 38679983
[TBL] [Abstract][Full Text] [Related]
2. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
Ali MAM; Bedair RN; Abd El Atti RM
Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
5. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
6. Human papilloma virus prevalence, genotype distribution, and pattern of infection in Thai women.
Suthipintawong C; Siriaunkgul S; Tungsinmunkong K; Pientong C; Ekalaksananan T; Karalak A; Kleebkaow P; Vinyuvat S; Triratanachat S; Khunamornpong S; Chongsuwanich T
Asian Pac J Cancer Prev; 2011; 12(4):853-6. PubMed ID: 21790214
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
10. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
11. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
Marembo T; Dube Mandishora R; Borok M
Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
14. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
16. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
17. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
19. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
20. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
